The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, InterMune's share price is €58.06.
InterMune's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2014 was €0.91. Hence, InterMune's PS Ratio for today is 64.08.
The historical rank and industry rank for InterMune's PS Ratio or its related term are showing as below:
FRA:IUX'
s PS Ratio Range Over the Past 10 Years
Min: 2.19 Med: 11.36 Max: 109.71
Current: 60.07
During the past 13 years, InterMune's highest PS Ratio was 109.71. The lowest was 2.19. And the median was 11.36.
FRA:IUX's PS Ratio is not ranked
in the Biotechnology industry.
Industry Median: 8.675
vs FRA:IUX: 60.07
InterMune Inc revenue has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of InterMune was 127.80% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -39.60% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -24.20% per year.
During the past 10 years, the average Revenue per Share Growth Rate was -23.40% per year.
During the past 13 years, InterMune's highest 3-Year average Revenue per Share Growth Rate was 91.60% per year. The lowest was -58.30% per year. And the median was -19.20% per year.
Back to Basics: PS Ratio
InterMune PS Ratio Historical Data
The historical data trend for InterMune's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, InterMune's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
InterMune's PS Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, InterMune's PS Ratio distribution charts can be found below:
* The bar in red indicates where InterMune's PS Ratio falls into.
InterMune PS Ratio Calculation
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
InterMune's Share Price of today is €58.06. InterMune's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2014 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.91.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
InterMune PS Ratio Related Terms
Thank you for viewing the detailed overview of InterMune's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
InterMune, Inc was incorporated in California in 1998 and reincorporated in Delaware in 2000 in connection with its initial public offering. InterMune is a biotechnology company focused on the research, development and commercialization of therapies in pulmonology and orphan fibrotic diseases. The Company's business is mainly focused on the development and commercialization of therapies within the specialized areas of pulmonology and orphan fibrotic diseases. It has an advanced-stage product candidate in pulmonology, pirfenidone that was granted marketing authorization effective February 2011 in all 27 member countries of the European Union for the treatment of adults with mild to moderate idiopathic pulmonary fibrosis. Pirfenidone is an orally active, small molecule compound under development for the treatment of idiopathic pulmonary fibrosis. Pirfenidone, a treatment for IPF, a progressive and fatal lung disease, has completed the global Phase 3 CAPACITY clinical development program. Actimmune is currently approved in the United States for the treatment of chronic granulomatous disease and severe, malignant osteopetrosis. Actimmune is also approved for commercial use in both indications in numerous other countries. CGD is a life-threatening congenital disorder that causes patients, mainly children, to be vulnerable to severe, recurrent bacterial and fungal infections. This results in frequent and prolonged hospitalizations and commonly results in death. Severe, malignant osteopetrosis is a life-threatening, congenital disorder that mainly affects children. This disease results in increased susceptibility to infection and an overgrowth of bony structures that might lead to blindness and/or deafness. The FDA and comparable regulatory agencies in state and local jurisdictions and in foreign countries impose substantial requirements upon the clinical development, manufacture and marketing of pharmaceutical products.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:IUX has been successfully added to your 